An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases.
Jad S HusseiniBárbara Juarez AmorimAngel Torrado-CarvajalVinay PrabhuDavid GrosharLale UmutluKen HerrmannLina García CañamaqueJosé Ramón García GarzónWilliam E PalmerPedram HeidariTiffany Ting-Fang ShihJacob SosnaCristina MatushitaJuliano CerciMarcelo QueirozValdair Francisco MugliaMarcello H Nogueira-BarbosaRonald J H BorraThomas C KweeAndor W J M GlaudemansLaura EvangelistaMarco SalvatoreAlberto CuocoloAndrea SoricelliChristian HeroldAndrea LaghiMarius MayerhoeferUmar MahmoodCiprian CatanaHeike E Daldrup-LinkBruce RosenOnofrio Antonio CatalanoPublished in: European journal of nuclear medicine and molecular imaging (2021)
PET/MR should be considered for staging of malignancies where there is a high likelihood of osseous metastatic disease based on the characteristics of the primary malignancy, hight clinical suspicious and in case, where the presence of osseous metastases will have an impact on patient management. Appropriate choice of tumor-specific radiopharmaceuticals, as well as stringent adherence to PET and MR protocols, should be employed.